GlassScriptPhysician profile
Nora Alghothani
NPI 1780837963
$529.00
in general payments reported to CMS, 2019-2025
10 companies · $39.97 in 2025
The $39.97 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $15.63 · 2022: $66.95 · 2023: $248 · 2024: $21.46 · 2025: $39.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $308.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $149.91 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Novo Nordisk INC | $143.68 | 2019-2023 | Wegovy |
| Dexcom, INC. | $110.52 | 2019-2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $32.12 | 2023 | Minimed 780g |
| Radius Health, INC. | $17.84 | 2023 | Tymlos |
| Tandem Diabetes Care, INC. | $17.37 | 2019 | |
| Amryt Pharma Holdings LTD | $16.81 | 2022 | |
| Ascendis Pharma Endocrinology INC | $15.70 | 2023 | |
| Mannkind Corporation | $13.34 | 2023 | Afrezza |
| Lilly USA, LLC | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Alghothani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.